APRI Score Calculator
Use this calculator to estimate the AST to Platelet Ratio Index (APRI), a common non-invasive score used in liver fibrosis assessment.
Educational use only. Clinical decisions should be made by qualified healthcare professionals.
If you have liver lab results and platelet count available, APRI can be a fast way to get a preliminary estimate of fibrosis risk. It is not a diagnosis by itself, but it is often used as part of broader clinical evaluation.
What is APRI?
APRI stands for AST to Platelet Ratio Index. It combines two values from routine blood work:
- AST (aspartate aminotransferase), a liver-related enzyme
- Platelet count, reported in billions per liter (10^9/L)
When AST rises and platelet counts fall, APRI tends to increase. Higher APRI values are associated with greater probability of liver fibrosis, especially in chronic liver disease contexts such as hepatitis C.
APRI Formula
The formula used in this calculator is:
Where:
- AST is your measured AST value (U/L)
- AST ULN is the laboratory upper limit of normal for AST (U/L)
- Platelet Count is in 10^9/L
How to Interpret APRI Scores
Common cutoffs (which can vary by guideline and clinical setting) are shown below:
| APRI Score | General Interpretation |
|---|---|
| < 0.5 | Lower likelihood of significant fibrosis |
| 0.5 to < 1.5 | Indeterminate range; additional tests may be needed |
| 1.5 to < 2.0 | Higher likelihood of significant fibrosis |
| ≥ 2.0 | Suggestive of advanced fibrosis/cirrhosis risk in some populations |
Step-by-Step Example
Suppose your lab values are:
- AST = 80 U/L
- AST ULN = 40 U/L
- Platelets = 150 (10^9/L)
Then:
An APRI of 1.33 sits in the indeterminate-to-higher-risk transition zone, so clinicians commonly correlate this with imaging, history, and other non-invasive markers.
When APRI is Useful
1) Initial Risk Stratification
APRI is often used as an inexpensive screening tool where advanced imaging or elastography is not immediately available.
2) Population and Resource-Limited Settings
Because APRI requires only common lab data, it is practical for broad clinical workflows and retrospective audits.
3) Follow-Up Trend Monitoring
While single-point values matter, trends over time can provide more context—especially when interpreted by a clinician familiar with the case.
Limitations You Should Know
- APRI does not directly measure fibrosis; it estimates risk probability.
- Performance differs across diseases (e.g., hepatitis C, hepatitis B, NAFLD, alcohol-associated liver disease).
- Acute inflammation, alcohol use, medications, and hematologic conditions can skew AST or platelet values.
- Different labs may use slightly different ULN values for AST, affecting the score.
APRI vs. Other Fibrosis Tools
APRI is one of several non-invasive tools. Others include FIB-4, transient elastography, and proprietary biomarker panels. APRI’s strengths are simplicity and accessibility, while its weakness is moderate sensitivity/specificity compared to multimodal approaches.
Best Practices for Using This Calculator
- Use the AST ULN reported by your own laboratory when possible.
- Confirm platelet units are in 10^9/L.
- Avoid making decisions from one number alone.
- Pair APRI with clinical examination, history, imaging, and additional blood-based indices.
Final Thoughts
The APRI calculator is a practical way to convert routine labs into an interpretable risk signal. It is especially useful for quick triage and educational understanding of liver fibrosis scoring. However, APRI is a support tool—not a standalone diagnostic test. Always review results with a healthcare professional for individualized interpretation and next steps.